Lovastatin
- Generic Name
- Lovastatin
- Brand Names
- Advicor, Altoprev
- Drug Type
- Small Molecule
- Chemical Formula
- C24H36O5
- CAS Number
- 75330-75-5
- Unique Ingredient Identifier
- 9LHU78OQFD
- Background
Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of Aspergillus terreus. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inh...
- Indication
Lovastatin is indicated to reduce the risk of myocardial infarction, unstable angina, and the need for coronary revascularization procedures in individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C. It is indicated as an intervention alternative in individuals presenting dyslipidemia...
- Associated Conditions
- Apolipoprotein, Cholesterol, LDL, Coronary Artery Atherosclerosis, Coronary Revascularization, Myocardial Infarction, Peripheral Arterial Disease (PAD), Unstable Angina Pectoris, Elevation of serum triglyceride levels, Total cholesterol increased
- Associated Therapies
- -
Neuroprotection With Statin Therapy for Acute Recovery Trial (Neu-START)
- First Posted Date
- 2005-10-25
- Last Posted Date
- 2016-05-09
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 33
- Registration Number
- NCT00243880
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
MARS - Monitored Atherosclerosis Regression Study
- Conditions
- First Posted Date
- 2005-07-01
- Last Posted Date
- 2009-12-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 270
- Registration Number
- NCT00116870
- Locations
- 🇺🇸
Atherosclerosis Research Unit, Division of Cardiovascular Medicine, Department of Medicine, Los Angeles, California, United States
Post Coronary Artery Bypass Graft (CABG) Study
- Conditions
Asymptomatic Carotid Artery Plaque Study (ACAPS)
Cholesterol Reduction in Seniors Program (CRISP)
Familial Atherosclerosis Treatment Study
- First Posted Date
- 1999-10-28
- Last Posted Date
- 2015-12-03
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 146
- Registration Number
- NCT00000512
Phase II Study of Cholesterol- and Cholestanol-Free Diet, Lovastatin, and Chenodeoxycholic Acid for Cerebrotendinous Xanthomatosis
- Conditions
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Target Recruit Count
- 5
- Registration Number
- NCT00004346
- Locations
- 🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.